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Table 2 : Adverse events during treatment (N=44)
Grades 1-2 
(%)
Grades 3-4 
(%)
Hematologic 
Neutropenia 13 (29.5) 12 (27.3)
Thrombocytopenia 29 (65.9) 4 (9.1)
 Cholangiocarcinomas are uncommon tumors arising as a result of
neoplastic transformation of epithelial cells covering bile ducts (1).
 Although rare, cholangiocarcinoma remains the second most common
hepatobiliary cancer (approximately 9000 new cases per year in the
United States) (2) and its incidence is increasing due to a better
knowledge of the disease and an improvement of diagnosis (3). The
only curative treatment of cholangiocarcinoma is surgical resection with
negative resection margins. At the time of diagnosis, more than two-
thirds of cholangiocarcinoma patients have unresectable disease (4).
PATIENTS CHARACTERISTICS
 A total of 44 patients from nine Belgian institutions affiliated to the
Belgian Group of Digestive Oncology (BGDO) were enrolled over 18
months (September 2008 to January 2010). Patients' characteristics
are summarized in table 1.
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Grade ≥ 2 Skin toxicity
Grade ≤ 1 Skin toxicity
Figure 1 : Kaplan-Meier curve for PFS
Table 1 : Baseline characteristics of the patients 
(N=44)
Anemia 33 (75.0) 5 (11.3)
Nonhematologic
Nausea 16 (36.4) 2 (4.5)
Vomiting 14 (31.8) 1 (2.3)
Diarrhea 13 (29.5) 0
Anorexia 6 (13.6) 1 (2.3)
Stomatitis 2 (4.5) 0
Fatigue 25 (56.8) 5 (11.3)
Liver dysfunction 1 (2.3) 2 (4.5)
Infection
Biliary tract 0 6 (13.6)
Other 2 (4.5) 1 (2.3)
Furthermore, patients who undergo curative surgery experience a high
tumor relapse rate (5).
 Recently, a randomized phase III trial has shown that the addition of
cisplatin to gemcitabine alone led to a significant improvement in overall
survival (median 11.7 vs 8.1 months) and in progression-free survival
(median 8.0 vs 5.0 months) (6).
 To improve anti-tumoral treatments, targeted therapies are also
explored.
 Epidermal growth factor-Receptor (EGFR or HER1) expression and
activation are particularly involved in tumor growth. It has been
RESPONSE ASSESSMENT AND PATIENT’S OUTCOME
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Figure 3 : Kaplan-Meier curve for 
PFS stratified by skin toxicity
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Figure 2 : Kaplan-Meier curve for OS
Age, years
Median (range) 61.5 (40-86)
Gender – No. (%)
Male 26 (59.1)
Female 18 (40.9)
ECOG performance status – No. (%)
0 30 (68.2)
1 14 (31.8)
Site of primary disease – No. (%)
Edema 3 (6.8) 0
Allergic reaction 2 (4.5) 0
Deep venous    
thrombosis
1 (2.3) 1 (2.3)
Hemolytic uremic 
syndrome
0 2 (4.5)
Nephrotic syndrome 0 1 (2.3)
Other 9 (20.5) 3 (6.8)
Skin toxicity 31 (70.5) 6 (13.6)
demonstrated that cholangiocarcinomas express mutated EGFR (7) but
also that EGFR can be overexpressed (8) (9). Cetuximab is a
chimerized IgG1 monoclonal antibody which blocks binding of EGF and
TGF-α to the EGFR.
 Based on early results, we designed a phase II study combining
cetuximab and gemcitabine in front line treatment of advanced
unresectable cholangiocarcinoma.
 Forty-three patients (98%) were assessable for response. Table 3
summarizes the response assessment parameters.
 Forty-six percent of the patients were progression-free at 6 months.
The median PFS time was 5.8 months (95%CI, 4.3 to 7.4 months).
Figure 1 shows the Kaplan-Meier curve for PFS.
The median OS time was 11.6 months (95% CI, 8.7 to 14.6 months)
with 46.6% of patients alive one year after study entry. At the time of
analysis, 24 patients (54.5%) are still alive. Figure 2 shows the Kaplan-
Meier curve for OS.
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Summary and conclusions
 The toxicity profile of the combination of gemcitabine and
Intrahepatic location 27 (61.4)
Distal  location 5 (11.4)
Perihilar location 12 (27.3)
Extent of disease – No. (%)
Locally advanced 18 (40.9)
Metastatic 26 (59.1)
Prior surgery – No. (%)
Yes 19 (43.2)
No 25 (56.8)
Patients and methods
KEY ELIGIBILITY CRITERIA AND STUDY DESIGN
GEMCITABINE AND CETUXIMAB ADMINISTRATIONS
 Patients received a total of 251 cycles of treatment (mean: 5.7
cycles per patient, range: 1 to 14 cycles per patient). Fifty-seven
percent of patients received between 2 and 6 cycles of study
treatment. At the cut-off date of analysis (31 July 2010), 7 patients
were still ongoing (mean duration of follow-up: 10.4± 3.1 months).
Nine patients achieved partial response (20.9%) with a median
duration of 5 months (range: 2 to 10 months). At the time of this
analysis, four of these nine patients were still ongoing on the trial.
Among these responders, 5 patients experienced a grade 2 skin toxicity
and 3 patients a grade 3 skin toxicity.
 Twenty-six patients (60.4%) achieved stable disease with a median
duration of 6 months (range: 6 to 12 months).
 The estimated overall response rate was 20.9% and disease control
rate was 81.4%.
The median PFS time was 7.2 months (95%CI, 4.8 to 9.6 months) in
cetuximab is manageable; no unexpected adverse events were
observed from adding cetuximab to gemcitabine.
 Progression-free survival rate at 6 months was 46%, which met
our predefined hypothesis. Median PFS was better for subjects
with a skin toxicity above or equal to grade 2. Overall response
rate was 20.9% and 1-year overall survival was 46.6%.
 This combination is promising and further investigations,
probably combining the cisplatine – gemcitabine doublet with
cetuximab, are warranted.
•Histologically or cytologically
confirmed cholangiocarcinoma, 
excluding gallbladder cancer, that
was surgically unresectable or 
CETUXIMAB
Initial dose of 400 mg/m² in a 120 min IV 
infusion 
ECOG = Eastern Cooperative Oncology Group
References
 The median duration of treatment was 19 weeks (range: 2 to 65
weeks).
TOXICITY
 All patients were assessable for toxicity. Table 2 summarizes all
adverse reactions reported during the trial according to NCI-CTC
(version 3.0).
 Most frequent grades 3-4 side effects were hematological
abnormalities (47.7%), biliary tract infections (13.6%), skin
patients with a skin toxicity above or equal to grade 2 and 3.2 months
(95%CI, 1.6 to 4.7 months) in patients with a skin toxicity below or equal
to grade 1, p = 0.012. Figure 3 shows Kaplan-Meier curve for PFS
stratified by skin toxicity.
 Additional study exploring relationship between K-Ras
mutational status, EGFR mutations, skin rash as predictive factor
for response and clinical outcome would be interesting.
metastatic
•Measurable disease, according to 
RECIST
•ECOG 0 or 1
•No prior systemic treatment
•Adequate hematological and 
biochemical parameters
•Age ≥ 18 years old
Further injections of 250 mg/m² in a 60 
min IV infusion
Every 7 days
+
GEMCITABINE
1000 mg/m² in a 30 min IV infusion
D1, D8 and D15 every 4 weeks
Treatment until disease progression, 
consent withdrawn, investigator’s
Table 3 : Response assessment
N=43
Partial response (PR)
No. (%) 9 (20.9)
OBJECTIVES
The primary endpoint of this trial was to evaluate progression-free
survival (PFS) at 6 months; secondary endpoints were to assess
response rate, safety and overall survival (OS). The statistical design
toxicity (13.6%) and fatigue (11.3%). Biliary tract infections were
considered to be related to study disease. There were no treatment
related deaths.
 Six patients (13.6%) discontinued study treatment because of
toxicity : two patients for prolonged grade 3 skin toxicity, one patient
for grade 4 skin toxicity, two patients for hemolytic-uremic syndrome
and one patient for nephrotic syndrome.
 Fourteen patients had a gemcitabine dose reduction (with one
patient at two dose levels) and 25 patients a dose interruption
(median : 1.1 week, range : 1 to 3 weeks) both mostly due to
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decision or unacceptable toxicity
Tumor assessements (CT or MRI) 
performed every 8 weeks
Duration (months) : Median (range) 5.0 (2-10)
Stable disease (SD)
No. (%) 26 (60.4)
Duration (months) : Median (range) 6 (2-12)
Disease control rate (%) 81.4 
Duration (months) : Median (range) 6 (2-12)
Progression-free survival (PFS) 
Median, 95%CI (months) 5.8 [4.3 – 7.4]
3-month PFS 76.7%
6-month PFS 46.0%
1-year PFS 19.8%
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was a Simon 2-stage design, built to improve 6-month PFS from 20% to
40%. After 3 patients within the first 13 met the criterion of 6-month
PFS, a total of 43 patients was needed in the study.
hematological toxicities. Regarding cetuximab, 3 patients had a dose
reduction (with one patient at two dose levels) and 9 patients a dose
interruption (median : 1.2 weeks, range : 1 to 3 weeks), both mostly
due to dermatological events
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N=44
Overall survival (OS) 
Median, 95%CI (months) 11.6 [8.7 – 14.6]
6-month OS 84.0%
1-year OS 46.6%
